Chronic hepatitis B (CHB) remains a significant unmetmedical need, with 240 million chronically infectedpersons worldwide. It can be controlled effectivelywith either nucleoside/nucleotide-based or interferonbasedtherapies. However, most patients receivingthese therapies will relapse after treatment withdrawal...
Critically, investments made by governments, academia and industry towards a potential functional cure have accelerated in the past decade, especially since the remarkable achievement of oral cures for chronic hepatitis C. However, many questions about HBV’s immunology, which we believe is key to ac...
Structure of mutant hepatitis B core protein capsids with premature secretion phenotype J. Mol. Biol. (2018) J.Changet al. Therapeutic strategies for a functional cure of chronic hepatitis B virus infection Acta Pharm. Sin. B (2014)
(GLOBE NEWSWIRE) --Gilead Sciences, Inc.(NASDAQ: GILD) andVir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed...
Hepatitis B virus (HBV) infection continues to be a major public health issue worldwide. HBsAg loss is associated with functional remission and improved long‐term outcome, and is considered to be a "functional cure" (also referred to as clinical or immunologic cure) for chronic hepatitis B. ...
Hepatitis B is a type of virus that causes serious infection in the liver. If not treated on time, hepatitis B can become chronic leading to permanent scarring or failure of liver function. Most often, hepatitis B can lead to major liver dysfunctions suc
Treatment of chronic hepatitis B virus (HBV) infection with the viral DNA polymerase inhibitors or pegylated alpha-interferon has led to a significant retardation in HBV-related disease progression and reduction in mortality related to chronic hepatitis B associated liver decompensation and hepatocellular ...
Exciting new data presented today at the International Liver Congress 2013 include results from early in vitro and in vivo studies targeting covalently closed circular DNA (cccDNA), which may form the basis of a cure for chronic hepatitis B virus (HBV) infection. ...
Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection Chronic infection with hepatitis B virus (HBV) occurs in approximately 6% of the world's population and carriers of...
"Our preclinical models have shown that birinapant kills infected liver cells, while not harming uninfected cells," he said. "Used in conjunction with an existing treatment for hepatitis B, this drug has the potential, for the first time, ...